Send to

Choose Destination
Medicine (Baltimore). 2014 Dec;93(28):e161. doi: 10.1097/MD.0000000000000161.

Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.

Author information

From the Skin Cancer Unit (EO, VU, CG, JU), German Cancer Research Center (DKFZ), Heidelberg; and Department of Dermatology, Venereology and Allergology (EO, BZ, VU, CG, JU), University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.


Recent advances in melanoma therapy have influenced the management of metastatic patients. Inhibitors of the BRAF/MEK/ERK signaling cascade have been proven highly effective in the metastatic disease although displaying different side effects. Here, we report a patient with BRAF V600E-mutated stage IV melanoma who developed a severe leukopenia upon targeted therapy with the BRAF inhibitor vemurafenib. Interestingly, the immediate therapeutic switch to a different BRAF inhibitor 'dabrafenib? had no negative influence on the leukocyte count. This case supports recent studies, which showed a differential influence of different BRAF inhibitors on patients' leukocytes despite similar clinical efficacy in melanoma.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center